Extracorporeal photopheresis (ECP) therapy is performed using the THERAKOS™ Photopheresis System.
Step 1
After removing whole blood from the patient the instrument centrifuges the blood to separate red blood cells (RBCs) from the leukocyte-containing buffy coat cells.
Step 2
The buffy coat cells remain in the THERAKOS™ Photopheresis System while other components are returned to the body.
Step 3
The buffy coat cells are treated with Methoxsalen Sterile Solution.
Step 4
The buffy coat cells are exposed to an automatically calculated amount (approximately 1.5 to 2 Joules/cm2) of UVA (ultraviolet-A) light to activate Methoxsalen Sterile Solution.
Step 5
The treated cells are then reinfused into the patient.
Specially designed for medical professionals to use in their practice.
Sherry's Experience
The Caregiver's Perspective
The Long Journey
About THERAKOS™ Photopheresis Treatment
How THERAKOS™ Photopheresis Works
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Indications
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.
